Skip to main content
Premium Trial:

Request an Annual Quote

Invitae, Nanopharmacia Partner on Genetic Cancer Testing in Mexico, Costa Rica, Panama

NEW YORK (GenomeWeb) – Invitae and Nanopharmacia today announced an exclusive partnership to provide access to Invitae's genetic tests for hereditary cancers in Mexico.

The deal also will make Invitae's tests available on a non-exclusive basis in Costa Rica and Panama. Financial and other terms were not disclosed.

Nanopharmacia, a provider of cancer molecular tests in Mexico and Latin America, will make Invitae's tests available to onco-geneticists and medical and surgical oncologists. Invitae offers single-gene BRCA1/2 testing, including full gene sequencing and deletion/duplication analysis, as well as a six-gene, high-risk hereditary breast cancer panel.

The San Francisco-based firm also offers an 18-gene women's hereditary cancer panel covering hereditary breast, ovarian, and endometrial cancer; a 29-gene hereditary cancer syndrome panel; a 17-gene hereditary pancreatic cancer panel; and other hereditary panels covering cancers including Lynch syndrome and colon cancers.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.